Neurofibromatosis type 2 (NF2): a clinical and molecular review
about
A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.Abdominal schwannoma in a case of neurofibromatosis type 2: A report of a rare combination.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasChildhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Tumor suppressor Nf2/merlin drives Schwann cell changes following electromagnetic field exposure through Hippo-dependent mechanisms.Mutations in LZTR1 add to the complex heterogeneity of schwannomatosisNeurofibromatosis type 2 patient presenting with medulloblastoma.Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.Neurofibromatosis type 2: Intracranial calcifications as a clue to diagnosismiRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathwaysGastrinoma and neurofibromatosis type 2: the first case report and review of the literature.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Radiographic association of schwannomas with sensory ganglia.Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Treatment of vestibular schwannoma cells with ErbB inhibitorsPreclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Temporal bone histopathology in neurofibromatosis type 2.Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.The molecular biology of vestibular schwannomas and its association with hearing loss: a review.Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy.A Rare Case of Radiologically Not Distinguishable Coexistent Meningioma and Vestibular Schwannoma in the Cerebellopontine Angle - Case Report and Literature Review.Angiosarcoma arising in schwannoma of cerebellopontine angle and later associating with meningioma in a patient with neurofibromatosis type 2.Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.A rare retroperitoneal schwannoma in a patient with neurofibromatosis Type 2.Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth PatternsA patient with mosaic neurofibromatosis type 2 presenting with early onset meningiomaAchieving consensus for clinical trials: the REiNS International Collaboration.Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2Recent developments in brain tumor predisposing syndromes.Role of Merlin/NF2 inactivation in tumor biology.Getting personal: Head and neck cancer management in the era of genomic medicine.Lisch and the Importance of His Nodules.The Conundrum of Genetic "Drivers" in Benign Conditions.The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.Malignancy in vestibular schwannoma after stereotactic radiotherapy: a case report and review of the literature.
P2860
Q30252766-7BC8E83F-2D12-4702-8C2B-1223AEF8EDCCQ30274790-02C040CF-8471-41A2-BB1D-231BD6BB6EB0Q30358638-1C6DDA3D-12AF-4561-B352-B5F794E43045Q30359059-579ACF71-8EF8-4758-8D0D-51160AA78643Q30364937-8D127CB4-BC2C-4A99-82D6-9538534D2B86Q30376040-C7D9817B-FD7D-4B7A-B005-25F4AC999C8AQ30394068-FAA2265F-AFB6-4566-8244-B12F83C35DFFQ30399531-5CEB7421-CB69-4FD2-9467-3C2809C76D91Q30405514-7960836C-82A3-4850-B074-DB04949B8C28Q30421923-2B42EAD8-D88A-4653-A5F3-64C7435AC1C3Q30428483-9E1A0A4B-7357-4DBC-9FB3-23E43D1A4A05Q30435359-36DEED37-FC86-46C4-AFBB-287EA4738A97Q30440530-A16D392E-8C02-4AD6-86C6-51F2A006FC86Q30450062-077C1406-AA7F-47A1-BF3A-5495132720EBQ30457595-F6855244-B463-4A94-A843-68BD12BFE43DQ30458310-E1ED3DAC-24A6-4C44-AC45-0430FF7CA239Q30458767-44858225-BE0B-4AD6-A9DB-D96242DE078DQ30459589-F635E2F1-AFF4-44EC-93A0-56FA7C5C65BFQ30464276-7EF686C3-D04D-4CF1-8F34-8C68B347D5FFQ30466218-168F4CA5-D540-4DD2-BADB-59AF4E9555FCQ30467373-16BFA3C1-6E96-4C0C-96A1-DB924AFE5B76Q30467803-DBACDCE0-313F-40DD-BC93-2F01D28EDFEBQ30477143-1E4D6CE8-013B-421F-AF73-496D1C92CFD3Q30478827-38AB8497-0ECA-4D9D-8857-D6422D86144AQ30771588-D586269F-8D7A-40E3-A5B8-13A63893BCF9Q33561323-8864A53F-E5EE-46B0-94BB-BDEE03012E52Q33816942-A8208307-C438-44DE-855A-631D7027B25CQ33828856-C2B8BB9E-08CB-4B3E-9C77-E69E5F5A8AE6Q33906075-222B2ADA-7D48-4D9A-BE82-FF77FFE6C2D3Q34573639-B971CA1D-2FB8-4F20-9441-036A404CE13DQ35046436-34BE7FF8-6854-4A88-B482-73CA10E40A50Q35047921-53D45419-02E1-4F85-A20E-77D7B1DC7184Q35380714-2733FA62-8DF5-42A8-90A5-BF3D7D6FC11DQ35860402-F63B2C64-DDD8-49C3-AC96-6162C6FE9D7CQ36189820-039DBB56-1C32-4376-8855-553D810F32AFQ36303715-190BCAB0-9815-42E1-9E99-4016E13621A9Q36345004-A829545A-39B8-41B4-9FF1-452CA5AAB82FQ37245787-B83B03E6-A59B-4135-A656-234437B4802CQ37601480-FC161D0B-CC44-464B-98BB-8785544EB502Q37869022-AEA505A2-4DC9-45CC-9464-700939C1974E
P2860
Neurofibromatosis type 2 (NF2): a clinical and molecular review
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@ast
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en-gb
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@nl
type
label
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@ast
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en-gb
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@nl
altLabel
Neurofibromatosis type 2 (NF2): A clinical and molecular review
@en
prefLabel
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@ast
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en-gb
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@nl
P2860
P3181
P356
P1476
Neurofibromatosis type 2 (NF2): a clinical and molecular review
@en
P2860
P2888
P3181
P356
10.1186/1750-1172-4-16
P407
P50
P5008
P577
2009-06-19T00:00:00Z
P5875
P6179
1017134341